Jupiter Neurosciences, Inc.

Jupiter Neurosciences, Inc. is a clinical stage research and development company focused on creating treatments for neuroinflammation using its unique resveratrol platform. The company's platform product, JOTROL™, is an enhanced oral formulation of resveratrol with many potential applications. In larger disease areas, Jupiter Neurosciences is primarily targeting Parkinson's Disease and is currently conducting a Phase IIa clinical trial for this condition. In March 2025, the company launched a new strategic initiative, Nugevia, a consumer-oriented product line for longevity and wellness. This initiative develops nutritional products to support consumer health and wellness, with formulations completed and initial direct-to-consumer (DTC) social media sales beginning in the second half of the year. In December 2024, the company received gross proceeds of $11 million from a registered public offering of 2,750,000 shares of its common stock, par value $0.0001 per share, at a price of $4.00 per share.